Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000139:chemically induced; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002648:Child; D004806:Ependymoma / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009460:Neurologic Examination; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced
D011034:Podophyllotoxin